Novartis Withdraws SANDIMMUNE Oral Solution Bottles Due to Crystallization
Novartis is recalling SANDIMMUNE Oral Solution bottles nationwide because they were found to contain crystals. Patients should contact their pharmacy or prescriber about affected bottles.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: FDA classified this as a Class I recall, which mandates a minimum severity score of 4. Although no illnesses or injuries are reported in the source, the crystallization found in bottles represents a defect in a prescription medication requiring Class I action.
Plain-English summary
Novartis Pharmaceuticals Corporation is recalling SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL distributed nationwide. The 50 mL bottles were found to contain crystals.
The recall affects 1,272 bottles with product code FX001691 and an expiration date of December 31, 2025.
Patients who have affected bottles should contact their pharmacy or prescriber immediately. Do not use the medication without guidance from your healthcare provider. Healthcare providers should verify lot codes in their inventory and remove affected product from dispensing.
The recalled product
- Product
- SANDIMMUNE Oral Solution (cyclosporine oral solution, USP) 100 mg/mL, 50 mL bottle, Rx Only, Manufactured by: DELPHARM Huningue S.A.S., Huningue, France, Distributed by: Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936, NDC 0078-0110-22.
- Manufacturer
- Novartis Pharmaceuticals Corp.
- Category
- Drug — Oral Solution
- Hazard
- crystallization
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- FX001691
- Exp. 12/31/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27